Share Price | Lyell Immunopharma, Inc. Stock Analysis & Recommendation

Q: How big is Lyell Immunopharma, Inc.?

Market Cap: As of Jun 18, Lyell Immunopharma, Inc. has a market capitalization of 143.64 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.06 million and a net profit of -334.53 million.Balance Sheet Snapshot: As of Dec 24, the shareholder's funds amounted to 382.82 million, while total assets were reported at 490.86 million.

Q: What does Lyell Immunopharma, Inc. do?

Overview: Lyell Immunopharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -52 Million (Quarterly Results - Mar 2025) Market-cap: USD 143.64 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.87 Return on Equity: -56.34% Price to Book: 0.43Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Lyell Immunopharma, Inc. overvalued or undervalued?

As of 29 February 2024, the valuation grade for Lyell Immunopharma, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company's current valuation suggests it is overvalued, particularly given its negative financial metrics. Key ratios include a price-to-book value of 0.56 and an EV to EBITDA of 0.50, which, while low, reflect the company's struggles rather than an attractive investment opportunity.In comparison to its peers, Lyell Immunopharma's valuation metrics are concerning. For instance, Scholar Rock Holding Corp. has a more negative EV to EBITDA of -9.8457, while Janux Therapeutics, Inc. shows a risky valuation with an EV to EBITDA of -3.1688. Furthermore, Lyell's return performance has been dismal, with a year-to-date decline of 29.77%, contrasting sharply with the S&P 500's 2.44% gain. Overall, the combination of negative ratios and poor market performance reinforces the view that Lyell Immunopharma is currently overvalued.

Q: Is Lyell Immunopharma, Inc. technically bullish or bearish?

As of 1 August 2025, the technical trend for Lyell Immunopharma, Inc. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish and bullish, respectively. However, the monthly indicators show a bearish trend in both the Bollinger Bands and KST. Overall, the mixed signals suggest a mildly bearish outlook. In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a 1-year return of -53.19% compared to the S&P 500's 17.14%, and a 3-year return of -91.21% versus 70.41% for the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

104.34 k

Shareholding (Sep 2025)

FII

18.01%

Held by 60 FIIs

DII

37.06%

Held by 12 DIIs

Promoter

33.52%

How big is Lyell Immunopharma, Inc.?

22-Jun-2025

As of Jun 18, Lyell Immunopharma, Inc. has a market capitalization of 143.64 million, with net sales of 0.06 million and a net profit of -334.53 million over the latest four quarters. Shareholder's funds are 382.82 million, and total assets are 490.86 million.

View full answer

What does Lyell Immunopharma, Inc. do?

22-Jun-2025

Lyell Immunopharma, Inc. is a micro-cap biotechnology company with no recent net sales and a net loss of $52 million as of March 2025. It has a market cap of $143.64 million and key metrics indicating significant financial challenges, including a negative return on equity and no dividend yield.

View full answer

Is Lyell Immunopharma, Inc. overvalued or undervalued?

25-Jun-2025

As of February 29, 2024, Lyell Immunopharma, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics and a year-to-date decline of 29.77%, significantly underperforming compared to the S&P 500's 2.44% gain.

View full answer

Is Lyell Immunopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of August 1, 2025, Lyell Immunopharma, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly over the past year and three years.

View full answer

Compare Lyell Immunopharma, Inc. with Similar Stocks

Edgewise Therapeutics, Inc.Scholar Rock Holding Corp.Aerovate Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 512 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.94

Return on Equity

-54.68%

Price to Book

1.56

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-43 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

41.94%

6 Months

99.12%

1 Year

87.82%

2 Years

-36.76%

3 Years

565.88%

4 Years

-80.0%

5 Years

0.0%

Lyell Immunopharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-71.63%

EBIT Growth (5y)

2.04%

EBIT to Interest (avg)

-218.23

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.87

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

56.38%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.56

EV to EBIT

0.46

EV to EBITDA

0.50

EV to Capital Employed

-2.39

EV to Sales

-103.99

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-56.34%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 37 Schemes (11.41%)

Foreign Institutions

Held by 60 Foreign Institutions (18.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 18.20% vs 72.80% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.50",
          "val2": "-54.00",
          "chgp": "23.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.40",
          "val2": "-1.30",
          "chgp": "-84.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-42.70",
          "val2": "-52.20",
          "chgp": "18.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,579,375.00%",
          "val2": "-8,212,285.70%",
          "chgp": "2,63,291.07%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -99.88% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -46.21% vs -28.13% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-204.30",
          "val2": "-230.50",
          "chgp": "11.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-156.10",
          "val2": "-14.80",
          "chgp": "-954.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-343.00",
          "val2": "-234.60",
          "chgp": "-46.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,670,344.30%",
          "val2": "-1,928,676.90%",
          "chgp": "-1,74,166.74%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-41.50

-54.00

23.15%

Interest

0.00

Exceptional Items

-2.40

-1.30

-84.62%

Consolidate Net Profit

-42.70

-52.20

18.20%

Operating Profit Margin (Excl OI)

-5,579,375.00%

-8,212,285.70%

2,63,291.07%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 18.20% vs 72.80% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.10

Operating Profit (PBDIT) excl Other Income

-204.30

-230.50

11.37%

Interest

0.00

Exceptional Items

-156.10

-14.80

-954.73%

Consolidate Net Profit

-343.00

-234.60

-46.21%

Operating Profit Margin (Excl OI)

-3,670,344.30%

-1,928,676.90%

-1,74,166.74%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -99.88% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -46.21% vs -28.13% in Dec 2023

All Annual Results

Company CV

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Lyell Immunopharma, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Lyell Immunopharma, Inc.?

Watch in Real-Time

What does Lyell Immunopharma, Inc. do?

Is Lyell Immunopharma, Inc. overvalued or undervalued?

Is Lyell Immunopharma, Inc. technically bullish or bearish?

Compare Lyell Immunopharma, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Lyell Immunopharma, Inc.

Company Coordinates